Global ADCs Market to Grow at a CAGR of 41.58% During the Period 2016 - 2020; Finds New Report
ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
View full press release